Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples (Q39418566)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples (English)

1 reference

Europe PubMed Central

11 September 2017

0 references

author name string

Christel Bonnas

1

1 reference

Europe PubMed Central

11 September 2017

Katja Specht

2

1 reference

Europe PubMed Central

11 September 2017

Olivia Spleiss

3

1 reference

Europe PubMed Central

11 September 2017

Stefanie Froehner

4

1 reference

Europe PubMed Central

11 September 2017

Gabriele Dietmann

5

1 reference

Europe PubMed Central

11 September 2017

Juliane M Krüger

6

1 reference

Europe PubMed Central

11 September 2017

Susanne Arbogast

7

1 reference

Europe PubMed Central

11 September 2017

Friedrich Feuerhake

8

1 reference

Europe PubMed Central

11 September 2017

language of work or name

0 references

publication date

28 February 2012

1 reference

Europe PubMed Central

11 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

11 September 2017

131

1 reference

Europe PubMed Central

11 September 2017

7

1 reference

Europe PubMed Central

11 September 2017

1621-1632

1 reference

Europe PubMed Central

11 September 2017

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Signal integration by JNK and p38 MAPK pathways in cancer development

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

PI3K/Akt signalling pathway and cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

MAP kinase signalling pathways in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Inferring tumor progression from genomic heterogeneity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Immunohistochemical assessment of protein phosphorylation state: the dream and the reality

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Preanalytical aspects: a neglected issue

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

A portrait of tissue phosphoprotein stability in the clinical tissue procurement process

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Stability of phosphoprotein as a biological marker of tumor signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Activation of NF-kappaB and MAP kinase cascades by hypothermic stress in endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Genetic predictors of MEK dependence in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27422

21 January 2018

Identifiers

10.1002/IJC.27422

1 reference

Europe PubMed Central

11 September 2017

release_z5g2tde7cvg27pzkpxlqdj4zvu

1 reference

https://api.fatcat.wiki/v0/release/z5g2tde7cvg27pzkpxlqdj4zvu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39418566&oldid=1840327729"